Catalent, Inc. (NYSE:CTLT) Position Increased by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its holdings in Catalent, Inc. (NYSE:CTLT) by 237.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 42,400 shares of the company’s stock after buying an additional 29,844 shares during the quarter. Handelsbanken Fonder AB’s holdings in Catalent were worth $1,905,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Thompson Siegel & Walmsley LLC grew its holdings in shares of Catalent by 46.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 704,322 shares of the company’s stock worth $32,069,000 after acquiring an additional 223,944 shares during the last quarter. Vanguard Group Inc. raised its holdings in Catalent by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after buying an additional 365,648 shares during the period. Tran Capital Management L.P. lifted its stake in Catalent by 12.2% during the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock valued at $16,258,000 after buying an additional 39,208 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Catalent by 43.1% in the third quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock worth $8,803,000 after buying an additional 58,240 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Catalent by 240.0% in the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after acquiring an additional 28,410 shares in the last quarter.

Analysts Set New Price Targets

CTLT has been the topic of a number of recent analyst reports. StockNews.com initiated coverage on shares of Catalent in a report on Saturday. They set a “sell” rating on the stock. UBS Group restated a “neutral” rating and issued a $63.50 target price (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. Stephens reissued an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Finally, Barclays lifted their target price on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $52.46.

Catalent Trading Up 0.2 %

Shares of NYSE CTLT opened at $55.92 on Friday. The stock has a market cap of $10.12 billion, a price-to-earnings ratio of -8.22, a PEG ratio of 6.04 and a beta of 1.20. The business has a 50 day simple moving average of $56.73 and a 200 day simple moving average of $48.58. Catalent, Inc. has a 52 week low of $31.45 and a 52 week high of $60.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The company’s quarterly revenue was down 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.62 EPS. On average, research analysts predict that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.